Biotech | July 16, 2022
Enveric Biosciences advances drug development for mental health indications
Advancing to IND-enabling studies with multiple drug candidates
Advancing to IND-enabling studies with multiple drug candidates
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Site Enhances New Modality CRDMO Platform Capacity for Customers
It includes both public and private health facilities including hospitals, clinics, diagnostic laboratories, and imaging centers
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Subscribe To Our Newsletter & Stay Updated
